ATYR
Price
$2.78
Change
-$0.18 (-6.08%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
263.02M
34 days until earnings call
SLDB
Price
$3.40
Change
-$0.29 (-7.86%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
263.86M
Ad is loading...

ATYR vs SLDB

Header iconATYR vs SLDB Comparison
Open Charts ATYR vs SLDBBanner chart's image
aTyr Pharma
Price$2.78
Change-$0.18 (-6.08%)
Volume$17.61K
Capitalization263.02M
Solid Biosciences
Price$3.40
Change-$0.29 (-7.86%)
Volume$4.6K
Capitalization263.86M
ATYR vs SLDB Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. SLDB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and SLDB is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ATYR: $2.96 vs. SLDB: $3.69)
Brand notoriety: ATYR and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 78% vs. SLDB: 60%
Market capitalization -- ATYR: $247.03M vs. SLDB: $263.86M
ATYR [@Biotechnology] is valued at $247.03M. SLDB’s [@Biotechnology] market capitalization is $263.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 1 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 1 green, 4 red.
According to our system of comparison, SLDB is a better buy in the long-term than ATYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • ATYR’s TA Score: 4 bullish, 5 bearish.
  • SLDB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATYR is a better buy in the short-term than SLDB.

Price Growth

ATYR (@Biotechnology) experienced а -8.64% price change this week, while SLDB (@Biotechnology) price change was -13.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

ATYR is expected to report earnings on May 07, 2025.

SLDB is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($264M) and ATYR($263M) have the same market capitalization . SLDB YTD gains are higher at: -7.750 vs. ATYR (-18.232). ATYR has higher annual earnings (EBITDA): -66.37M vs. SLDB (-121.9M). SLDB has more cash in the bank: 149M vs. ATYR (72.1M). ATYR has less debt than SLDB: ATYR (13.3M) vs SLDB (24.2M). ATYR has higher revenues than SLDB: ATYR (235K) vs SLDB (0).
ATYRSLDBATYR / SLDB
Capitalization263M264M100%
EBITDA-66.37M-121.9M54%
Gain YTD-18.232-7.750235%
P/E RatioN/AN/A-
Revenue235K0-
Total Cash72.1M149M48%
Total Debt13.3M24.2M55%
FUNDAMENTALS RATINGS
ATYR vs SLDB: Fundamental Ratings
ATYR
SLDB
OUTLOOK RATING
1..100
5856
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
5293
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
47n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (37) in the Biotechnology industry is somewhat better than the same rating for ATYR (81) in the null industry. This means that SLDB’s stock grew somewhat faster than ATYR’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATYR (100) in the null industry. This means that SLDB’s stock grew similarly to ATYR’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as ATYR (98) in the null industry. This means that SLDB’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (52) in the null industry is somewhat better than the same rating for SLDB (93) in the Biotechnology industry. This means that ATYR’s stock grew somewhat faster than SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ATYR (100) in the null industry. This means that SLDB’s stock grew significantly faster than ATYR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRSLDB
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
80%
Bullish Trend 23 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICEIX22.17N/A
N/A
Macquarie International Core Eq I
IVRSX28.54N/A
N/A
VY® CBRE Real Estate S
GLOSX19.31N/A
N/A
Victory Pioneer Global Equity A
LAFSX18.66N/A
N/A
Lord Abbett Affiliated R4
GMNAX10.43N/A
N/A
Gabelli Global Mini Mites A

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+2.78%
MGTX - ATYR
43%
Loosely correlated
+3.25%
NTLA - ATYR
36%
Loosely correlated
+9.69%
SLDB - ATYR
35%
Loosely correlated
+7.11%
ARWR - ATYR
34%
Loosely correlated
+3.97%
AMLX - ATYR
34%
Loosely correlated
+13.17%
More